A Vaccine the World Badly Needs Looks Better Than Ever

Research and manufacturing delays have dogged the arrival of a Covid-19 vaccine from Novavax Inc., one of only six selected by the U.S. government's Operation Warp Speed for a large order. At one point in May, the company’s shares were down 62% from a Febru

On Monday, though, Novavax took a step toward a comeback, announcing that its vaccine was 90.4% effective in preventing mild and moderate Covid in a large trial in the U.S. and Mexico and prevented all severe disease.

Read more at: https://www.bloombergquint.com/gadfly/novavax-vaccine-data-impresses-in-variant-fight